Citation Tools
PDFRegular and young investigator award abstracts
Clinical trials in progress
399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial